AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30285518 — intervention group
Group type: EXPERIMENTAL
Intervention: Telisotuzumab vedotin (Teliso-V) 2.4 to 3.0 mg/kg
Number of subjects: 48
Study 30285518 — intervention group
Group type: EXPERIMENTAL
Intervention: Telisotuzumab vedotin (Teliso-V)
Number of subjects: 48
Study 30285651 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-defining NASH group (n=38)
Number of subjects: 88
Study 30285651 — intervention group
Group type: EXPERIMENTAL
Intervention: NASH group (n=18)
Number of subjects: 88
Study 30285651 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=12)
Number of subjects: 88
Study 30285651 — intervention group
Group type: EXPERIMENTAL
Intervention: All NAFLD groups
Number of subjects: 88
Study 30285651 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum ALT and YY1 levels
Number of subjects: 88
Study 30285741 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal pressure measurement
Number of subjects: 9
Study 30285741 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric pressure measurement
Number of subjects: 9
Study 30285741 — intervention group
Group type: EXPERIMENTAL
Intervention: Superior vena cava pressure measurement
Number of subjects: 9
Study 30285741 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal pressure measurement
Number of subjects: 9
Study 30285741 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder pressure measurement
Number of subjects: 9
Study 30285767 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-item Herth Hope Index (HHI)
Number of subjects: 167
Study 30285767 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-item Herth Hope Index (HHI)
Number of subjects: 167
Study 30285990 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfiltered nanofat injections
Number of subjects: 48
Study 30286325 — intervention group
Group type: EXPERIMENTAL
Intervention: First episode psychosis (FEP) patients
Number of subjects: 14
Study 30286325 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 14
Study 30286396 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion regulation difficulties
Number of subjects: 73
Study 30286396 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative social control from close others
Number of subjects: 73
Study 30286396 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive social control from close others
Number of subjects: 73
Study 30286520 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting bioresorbable vascular scaffolds
Number of subjects: 812
Study 30286724 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-therapeutic dynapenia (HGS <30 kg for men and <20 kg for women)
Number of subjects: 201
Study 30286724 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy regimen (FOLFOX: 5FU, leucovorin plus oxaliplatin)
Number of subjects: 201
Study 30286739 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SABR)
Number of subjects: 200
Study 30286776 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious games (SG) rehabilitation exercises using Kinect sensor
Number of subjects: 27
Study 30286776 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious games (SG) rehabilitation exercises
Number of subjects: 27
Study 30286821 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineralocorticoid receptor antagonist (MRA) therapy
Number of subjects: 12
Study 30287268 — intervention group
Group type: EXPERIMENTAL
Intervention: Online eating disorder diagnostic questionnaire (ED100K-v1)
Number of subjects: 13363
Study 30287268 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Clinical Interview for DSM-IV (SCID), Module H
Number of subjects: 13363
Study 30287268 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment via national registers, treatment centers, and social media
Number of subjects: 13363
Study 30287268 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet/social media recruitment
Number of subjects: 13363
Study 30287613 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring (TDM) of second-line antituberculosis drugs
Number of subjects: 0
Study 30287613 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug concentrations of pyrazinamide, ethambutol, levofloxacin, moxifloxacin, cycloserine, prothionamide, para-aminosalicylate, and amikacin
Number of subjects: 0
Study 30287613 — intervention group
Group type: EXPERIMENTAL
Intervention: MIC determination of pyrazinamide and other drugs
Number of subjects: 0
Study 30287613 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical scoring tool (TBscore II)
Number of subjects: 0
Study 30287613 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D-5L
Number of subjects: 0
Study 30287673 — intervention group
Group type: EXPERIMENTAL
Intervention: Core treatment for osteoarthritis in primary healthcare
Number of subjects: 75000
Study 30287855 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropeginterferon alpha-2b
Number of subjects: 0
Study 30287855 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyurea
Number of subjects: 0
Study 30288127 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-call smoking cessation intervention (8 sessions of 30 minutes each, with active nicotine patches for 8 weeks)
Number of subjects: 0
Study 30288127 — intervention group
Group type: COMPARATOR
Intervention: Voice-call smoking cessation intervention (8 sessions of 30 minutes each, with active nicotine patches for 8 weeks)
Number of subjects: 0
Study 30288327 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin-α 550 mg
Number of subjects: 550
Study 30288700 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab (0.5 mg) injections
Number of subjects: 1226
Study 30289374 — intervention group
Group type: EXPERIMENTAL
Intervention: Family meetings as a prevention strategy
Number of subjects: 82
Study 30289374 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilience-focused family intervention (Our Family Our Future)
Number of subjects: 82
Study 30289425 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein (WP) supplementation (30 g, 2 times/d)
Number of subjects: 31
Study 30289425 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen peptides (CP) supplementation (30 g, 2 times/d)
Number of subjects: 31
Study 30289425 — intervention group
Group type: COMPARATOR
Intervention: Energy restriction (ER; -500 kcal/d) followed by ER with step reduction (ER + SR; <750 steps/d)
Number of subjects: 31
Study 30289433 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 124707
Study 30289433 — intervention group
Group type: EXPERIMENTAL
Intervention: AMED diet
Number of subjects: 124707
Study 30289433 — intervention group
Group type: EXPERIMENTAL
Intervention: AHEI-2010 diet
Number of subjects: 124707
Study 30289433 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet (men)
Number of subjects: 124707
Study 30289433 — intervention group
Group type: EXPERIMENTAL
Intervention: AMED diet (men)
Number of subjects: 124707
Study 30289433 — intervention group
Group type: EXPERIMENTAL
Intervention: AHEI-2010 diet (men)
Number of subjects: 124707
Study 30289433 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet (women)
Number of subjects: 124707
Study 30289433 — intervention group
Group type: EXPERIMENTAL
Intervention: AMED diet (women)
Number of subjects: 124707
Study 30289433 — intervention group
Group type: EXPERIMENTAL
Intervention: AHEI-2010 diet (women)
Number of subjects: 124707
Study 30289500 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-measured arm circumference (CIRself_home)
Number of subjects: 41
Study 30289500 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-measured arm circumference (CIRself_lab)
Number of subjects: 41
Study 30289500 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-measured arm volume (VOLself_lab)
Number of subjects: 41
Study 30289500 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-managed surveillance for BCRL
Number of subjects: 41
Study 30289497 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced anxiety during MID task
Number of subjects: 0
Study 30289507 — intervention group
Group type: COMPARATOR
Intervention: Normal ovulatory cycles (normal OVs)
Number of subjects: 23
Study 30289507 — intervention group
Group type: EXPERIMENTAL
Intervention: Anovulatory cycles (ANOVs)
Number of subjects: 23
Study 30289507 — intervention group
Group type: EXPERIMENTAL
Intervention: Short luteal phase ovulatory cycles (short OVs)
Number of subjects: 23
Study 30289805 — intervention group
Group type: EXPERIMENTAL
Intervention: TriMix-100 g
Number of subjects: 21
Study 30289805 — intervention group
Group type: EXPERIMENTAL
Intervention: TriMix-300 g
Number of subjects: 21
Study 30289805 — intervention group
Group type: EXPERIMENTAL
Intervention: TriMix-300 g with HTI-300 g
Number of subjects: 21
Study 30289805 — intervention group
Group type: EXPERIMENTAL
Intervention: TriMix-300 g with HTI-600 g
Number of subjects: 21
Study 30289805 — intervention group
Group type: EXPERIMENTAL
Intervention: TriMix-300 g with HTI-900 g
Number of subjects: 21
Study 30290003 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 1121
Study 30290003 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib
Number of subjects: 1121
Study 30290003 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib
Number of subjects: 1121
Study 30290121 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives for smoking cessation
Number of subjects: 0
Study 30290121 — intervention group
Group type: COMPARATOR
Intervention: Cessation aids
Number of subjects: 0
Study 30290794 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal hydromorphone
Number of subjects: 20
Study 30290829 — intervention group
Group type: EXPERIMENTAL
Intervention: Noise levels in the ICU
Number of subjects: 64
Study 30290829 — intervention group
Group type: EXPERIMENTAL
Intervention: Restorative periods
Number of subjects: 64
Study 30290829 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 64
Study 30291058 — intervention group
Group type: EXPERIMENTAL
Intervention: Health technology-supported self-management program involving telemonitoring and health counseling
Number of subjects: 166
Study 30291058 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 166
Study 30291086 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology use in diabetes management
Number of subjects: 260
Study 30291086 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to technology
Number of subjects: 260
Study 30291086 — intervention group
Group type: EXPERIMENTAL
Intervention: Ownership of a home computer
Number of subjects: 260
Study 30291092 — intervention group
Group type: EXPERIMENTAL
Intervention: OneTouch Verio Flex glucose meter with OneTouch Reveal diabetes app
Number of subjects: 137
Study 30291092 — intervention group
Group type: COMPARATOR
Intervention: OneTouch Verio Flex glucose meter alone
Number of subjects: 137
Study 30291094 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone Messaging (PM)
Number of subjects: 42
Study 30291094 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone Messaging plus Family and Friends Support (PM+FF)
Number of subjects: 42
Study 30291094 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 42
Study 30291112 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab 600 mg weekly for 4 weeks, then 900 mg every other week through week 26
Number of subjects: 13
Study 30291369 — intervention group
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir 25/150/100 mg once daily ± dasabuvir 250 mg twice daily ± ribavirin 200 mg once daily for 12 or 24 weeks
Number of subjects: 86
Study 30291369 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin
Number of subjects: 86
Study 30291369 — intervention group
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir, dasabuvir, and ribavirin
Number of subjects: 86
Study 30291377 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler-based resistive index (RI)
Number of subjects: 371
Study 30291377 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-quantitative evaluation of renal perfusion (SQP)
Number of subjects: 371
Study 30291379 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher neutrophil CD279
Number of subjects: 272
Study 30291379 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher monocyte CD279
Number of subjects: 272
Study 30291379 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower monocyte HLA-DR
Number of subjects: 272
Study 30291379 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased neutrophil CD24 and neutrophil CD279, reduced monocyte HLA-DR expression
Number of subjects: 272
Study 30291587 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenojejunostomy ± distal duodenum resection
Number of subjects: 39
Study 30291761 — intervention group
Group type: EXPERIMENTAL
Intervention: CAMS
Number of subjects: 98
Study 30291761 — intervention group
Group type: COMPARATOR
Intervention: E-CAU
Number of subjects: 98
Study 30291831 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartMate 3 left ventricular assist device (ELEVATE registry)
Number of subjects: 463
Study 30291831 — intervention group
Group type: COMPARATOR
Intervention: HeartMate 3 left ventricular assist device (CEM trial)
Number of subjects: 463
Study 30291834 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine toothbrushing three times daily for 5 days before and after surgery
Number of subjects: 62
Study 30291834 — intervention group
Group type: COMPARATOR
Intervention: Time-matched control group (no specific intervention mentioned)
Number of subjects: 62
Study 30291834 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine toothbrushing
Number of subjects: 62
Study 30291925 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-low-dose CT scans (0.14 mSv)
Number of subjects: 105
Study 30291925 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose CT scans (3.4 mSv)
Number of subjects: 105
Study 30292492 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial ultrasonography and near-term MRI
Number of subjects: 397
Study 30292492 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of lesions on near-term MRI
Number of subjects: 397
Study 30292492 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive screens on Competence scores
Number of subjects: 397
Study 30292651 — intervention group
Group type: EXPERIMENTAL
Intervention: MR haplotype 1 (G-A haplotype)
Number of subjects: 469
Study 30292651 — intervention group
Group type: EXPERIMENTAL
Intervention: MR haplotypes
Number of subjects: 469
Study 30292675 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted ketogenic diet (AKD)
Number of subjects: 24
Study 30292675 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR)
Number of subjects: 24
Study 30292675 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 30293206 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone deficiency defined by total testosterone (TT) levels < 300 ng/dL and/or bioavailable testosterone (BT) levels < 80 ng/dL
Number of subjects: 1343
Study 30293206 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone deficiency (TT and/or BT levels)
Number of subjects: 1343
Study 30293206 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioavailable testosterone (BT) levels
Number of subjects: 1343
Study 30293228 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative treatment strategies for diabetic retinopathy targeting retinal neuroprotection, promoting neuronal regeneration, and re-programming retinal cell types into functional neurons.
Number of subjects: 0
Study 30293228 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular mechanisms and potential biomarkers associated with retinal neuronal degeneration in diabetes.
Number of subjects: 0
Study 30293250 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) fluorescence imaging (FI)
Number of subjects: 19
Study 30293640 — intervention group
Group type: EXPERIMENTAL
Intervention: Bardet-Biedl syndrome (BBS) subjects with thoraco-abdominal abnormalities
Number of subjects: 368
Study 30293640 — intervention group
Group type: EXPERIMENTAL
Intervention: Bardet-Biedl syndrome (BBS) subjects with congenital heart disease
Number of subjects: 368
Study 30293640 — intervention group
Group type: EXPERIMENTAL
Intervention: Bardet-Biedl syndrome (BBS) subjects with additional defects
Number of subjects: 368
Study 30293873 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI plus bevacizumab (discovery cohort)
Number of subjects: 451
Study 30293873 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI plus bevacizumab (validation cohort)
Number of subjects: 451
Study 30293873 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI plus cetuximab (control cohort)
Number of subjects: 451
Study 30294448 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive therapy (MCT)
Number of subjects: 246
Study 30294448 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 246
Study 30294474 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon-mounted stent
Number of subjects: 300
Study 30294474 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon plus self-expanding stent
Number of subjects: 300
Study 30294474 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (both interventions)
Number of subjects: 300
Study 30294552 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin pump therapy
Number of subjects: 156
Study 30294552 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily insulin injections (MDI)
Number of subjects: 156
Study 30294699 — intervention group
Group type: EXPERIMENTAL
Intervention: Fit&Trim (DPP-based) intervention
Number of subjects: 67
Study 30294699 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 67
Study 30294708 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.8 g/day multimatrix mesalamine tablets once daily for eight weeks (acute phase)
Number of subjects: 717
Study 30294708 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.4 g/day multimatrix mesalamine for 12 months (maintenance phase)
Number of subjects: 717
Study 30294708 — intervention group
Group type: COMPARATOR
Intervention: Comparison of SF-12v2 scores to the U.S. general population
Number of subjects: 717
Study 30294708 — intervention group
Group type: COMPARATOR
Intervention: Mixed-effects repeated-measures models
Number of subjects: 717
Study 30295389 — intervention group
Group type: EXPERIMENTAL
Intervention: Episodic treatment (n=75)
Number of subjects: 103
Study 30295389 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic treatment (n=28)
Number of subjects: 103
Study 30295389 — intervention group
Group type: EXPERIMENTAL
Intervention: aPCC prophylaxis
Number of subjects: 103
Study 30295389 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious adverse events (AEs)
Number of subjects: 103
Study 30295700 — intervention group
Group type: EXPERIMENTAL
Intervention: Cow milk formula (CMF)
Number of subjects: 113
Study 30295700 — intervention group
Group type: COMPARATOR
Intervention: Extensively protein hydrolyzed formula (EHF)
Number of subjects: 113
Study 30295816 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clomiphene citrate (50 mg) once daily for 30 days
Number of subjects: 12
Study 30295822 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic malaria infections with P. cynomolgi
Number of subjects: 5422
Study 30295822 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic malaria infections with P. knowlesi
Number of subjects: 5422
Study 30295822 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic malaria infections with both P. vivax and P. cynomolgi
Number of subjects: 5422
Study 30295822 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic reappearance of P. cynomolgi
Number of subjects: 5422
Study 30295822 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall asymptomatic malaria infections
Number of subjects: 5422
Study 30296432 — intervention group
Group type: EXPERIMENTAL
Intervention: NICE classification system
Number of subjects: 1634
Study 30296681 — intervention group
Group type: EXPERIMENTAL
Intervention: pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine followed by TA-HPV boost through skin scarification
Number of subjects: 0
Study 30296735 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid use (yes)
Number of subjects: 144
Study 30296735 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain intensity (stronger)
Number of subjects: 144
Study 30296735 — intervention group
Group type: COMPARATOR
Intervention: Pain intensity (mild)
Number of subjects: 144
Study 30296735 — intervention group
Group type: COMPARATOR
Intervention: Pain intensity (moderate to severe)
Number of subjects: 144
Study 30296840 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine with aura patients
Number of subjects: 22
Study 30296840 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 22
Study 30297124 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine (qHPV) administered at 0, 2, and 6 months
Number of subjects: 189
Study 30297124 — intervention group
Group type: COMPARATOR
Intervention: Historical controls (HIV-1-negative cohorts from Africa and HIV-1 positive adolescent cohorts from the USA)
Number of subjects: 189
Study 30297124 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine (qHPV)
Number of subjects: 189
Study 30297385 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib 300 mg orally every day plus bortezomib 1.3 mg/m² IV on days 1, 4, 8, and 11 of a 28-day cycle
Number of subjects: 22
Study 30297543 — intervention group
Group type: EXPERIMENTAL
Intervention: LVIS stent system (LVIS and LVIS Junior) used for coil embolization
Number of subjects: 153
Study 30297879 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rhEPO) treatment
Number of subjects: 78
Study 30297879 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaemia during postnatal week 1
Number of subjects: 78
Study 30297879 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational age (GA)
Number of subjects: 78
Study 30297879 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated EPO levels postnatal day 7
Number of subjects: 78
Study 30298037 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for Insomnia Severity, details not available
Number of subjects: 0
Study 30298065 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0